A phase I clinical research also supported that Ivuxolimab (a TNFRSF4 agonist) showed well tolerance and effective anti-tumor capacity in locally advanced or metastatic cancers, including HCC [37]. This evidence concerns the gene TNFRSF4 and hepatocellular carcinoma.